Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Mar 26, 2025 · FDA has approved zenocutuzumab (Bizengri) to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion.
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in
Dec 8, 2025 · In December 2024, zenocutuzumab-zbco (BIZENGRI ®) received U.S. Food and Drug Administration accelerated approval for the treatment of adults with advanced unresectable or …
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients …
Dec 6, 2025 · "The durable responses and manageable safety profile of zenocutuzumab offer renewed hope and reinforce the need for continued innovation in biomarker-driven lung cancer care."
Phase 2 eNRGy Trial: Zenocutuzumab Shows ‘Early and Durable …
5 days ago · Zenocutuzumab showed “clinically meaningful early and durable responses” in patients with NRG1 -positive non–small cell lung cancer (NSCLC), with a longer duration of response in …
Zenocutuzumab Yields Durable Responses in Treatment-Naive …
Dec 8, 2025 · Zenocutuzumab-zbco (Bizengri) showed potential in patients with treatment-naive non–small cell lung cancer (NSCLC) harboring an NRG1 gene fusion in results from a post hoc …
FDA Approves Zenocutuzumab-zbco to Treat Non-small Cell Lung Cancer …
Feb 20, 2025 · On 4 December 2024, FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri®) for the treatment of adults with advanced, unresectable, or metastatic non-small cell lung …
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With …
Feb 6, 2025 · The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene …
Efficacy and safety of zenocutuzumab, a HER2/HER3 bispecific antibody, in treatment-naïve, advanced NRG1+ NSCLC: Updated analysis from the ongoing phase 2 eNRGy trial
Zenocutuzumab: Uses in Cancer, Side Effects, Dosages, Expectations, …
Mar 3, 2025 · What Cancers Is Zenocutuzumab Approved to Treat? Zenocutuzumab has received FDA approval for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and …
Accelerated approval for drug targeting NRG1 - Lung Cancer Research ...
Jan 14, 2025 · The good news The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable, or …